CVS Jumping on Cost-plus Bandwagon
Pharmacy benefit managers have been under pressure to simplify their complicated, obscure pricing tactics.
CVS Health is joining pharmacy benefit managers by offering simpler, cost-plus pricing, although it won't be available until 2025.
“CVS CostVantage will define the drug cost and related reimbursement with contracted pharmacy benefit managers (PBMs) and payers, using a transparent formula built on the cost of the drug, a set markup, and a fee that reflects the care and value of pharmacy services,” the company said in a news release this morning in advance of its investor’s day event.
CVS Pharmacy plans to launch CVS CostVantage with PBMs for their commercial payers in 2025, according to the news release.
The news release also announced the launch of a program called TrueCost, which the company will offer “client pricing reflecting the true net cost of prescription drugs, with visibility into administrative fees.” It will also be available in 2025.
Cigna Group’s Express Scripts announced plans to offer a “cost-plus” drug pricing model in November.
Pharmacy benefit managers (PBMs) especially the ‘big three” — CVS Caremark, Express Scripts and Optum Rx — have been under pressure to make their complicated, often obscure pricing tactics more transparent. Mark Cuban, the owner of the NBA’s Dallas Mavericks and a “Shark Tank” judge, co-founded Mark Cuban Cost Plus Drugs in early 2022 with a simple mark-up pricing strategy that Express Scripts and CVS Caremark appear to be emulating.
Several PBM reform bills have been introduced in Congress that would also require more reporting and transparency.
Healthcare Leaders Warn GOP Plan Would Deeply Chip Away At Medicaid Access
May 12th 2025Their concerns come in response to the bill unveiled Sunday night by House Republicans that would tighten eligibility rules, create work requirements and freeze provider taxes under Medicaid—the federal-state program that insures nearly 80 million low-income Americans.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Lack of Social Support Top Barrier to Cell and Gene Therapy Access, Survey Finds
May 12th 2025Healthcare providers are exploring ways to reduce patient travel through a growing trend of expanding sites of administration beyond academic medical centers into community and outpatient settings closer to patients' homes.
Read More
Survey Reveals Cancer Doctors Struggle to Keep Up as Treatments Advance Quickly
May 11th 2025A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.
Read More
